Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway

Fig. 3

Dasatinib treatment decreased CDDP-resistance and stemness of NSCLC cells. a Comparative MTT assay showed that when A549R and H460R cells were first treated with dasatinib (1 μM, 24 h) followed by CDDP treatment demonstrated an increased sensitivity towards CDDP. b Tumor sphere formation assay showed that dasatinib treatment (10 μM) significantly inhibited the formation of tumor spheres in both A549R and H460R cells. c Flow cytometry analysis of CD133+ cells. Dasatinib treatment dose-dependently decreased the percentage of CD133+ cell population in both H460R and A549R cells. The bar graph on the right shows the comparative level of CD133+ cell population (from the flow cytometric analysis on the left) under different concentration of dasatinib treatment. *P < 0.05 as compared to the control. d Expression profiling of A549R and H460R post dasatinib treatment (5 μM, 24 h). The expression of pro-tumorigenesis molecules, Src, CD155 and MIF, cancer stemness molecules, Notch1 and β-catenin was all significantly suppressed under dasatinib treatment

Back to article page